The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Open accessAbstract
The promise of bispecific antibodies (bsAbs) to yield more effective therapeutics is well recognized; however, the generation of bsAbs in a practical and cost-effective manner has been a formidable challenge. Here we present a technology for the efficient generation of bsAbs with normal IgG structures that is amenable to both antibody drug discovery and development. The process involves separate expression of two parental antibodies, each containing single matched point mutations in the CH3 domains. The parental antibodies are mixed and subjected to controlled reducing conditions in vitro that separate the antibodies into HL half-molecules and allow reassembly and reoxidation to form highly pure bsAbs. The technology is compatible with standard large-scale antibody manufacturing and ensures bsAbs with Fc-mediated effector functions and in vivo stability typical of IgG1 antibodies. Proof-of-concept studies with HER2×CD3 (T-cell recruitment) and HER2×HER2 (dual epitope targeting) bsAbs demonstrate superior in vivo activity compared with parental antibody pairs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., et al. (2007) · Science · doi:10.1126/science.1144603 · Cited by 975
Self-citationTherapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592
Hybrid hybridomas and their use in immunohistochemistry
Milstein, C., & Cuello, A. C. (1983) · Nature · doi:10.1038/305537a0 · Cited by 517
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Schaefer, W., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019002108 · Cited by 482
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1345 · Cited by 344
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Adams, C. W., Allison, D. E., Flagella, K., Presta, L., Clarke, J., Dybdal, N., McKeever, K., & Sliwkowski, M. X. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0058-x · Cited by 316
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Labrijn, A. F., Buijsse, A. O., van den Bremer, E. T. J., Verwilligen, A. Y. W., Bleeker, W. K., Thorpe, S. J., Killestein, J., Polman, C. H., Aalberse, R. C., Schuurman, J., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1553 · Cited by 298
Self-citationEnhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects
Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S. B., Born, T., Retter, M., Manchulenko, K., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.117382 · Cited by 280
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Friedman, L. M., Rinon, A., Schechter, B., Lyass, L., Lavi, S., Bacus, S. S., Sela, M., & Yarden, Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409610102 · Cited by 252
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213 · cited 1×
“, common L chain (7), speciesrestricted H-L chain pairing (8), crossover of CL and CH1 domains (9)] in combination with strategies to promote heterodimerization of the two H chains [e.”
BackgroundDavis, J. H., Aperlo, C., Li, Y., Kurosawa, E., Lan, Y., Lo, K.-M., & Huston, J. S. (2010) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzp094 · Cited by 194
Mechanism of Immunoglobulin G4 Fab-arm Exchange
Rispens, T., Ooijevaar-de Heer, P., Bende, O., & Aalberse, R. C. (2011) · Journal of the American Chemical Society · doi:10.1021/ja203638y · Cited by 184
Ben-Kasus, T., Schechter, B., Lavi, S., Yarden, Y., & Sela, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812059106 · Cited by 172
Current approaches and future directions in the treatment of HER2-positive breast cancer
Hurvitz, S. A., Hu, Y., O’Brien, N. A., & Finn, R. S. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.008 · Cited by 168
Bispecific human IgG by design
Carter, P. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00339-2 · Cited by 167
A revival of bispecific antibodies
Kufer, P., Lutterbüse, R., & Baeuerle, P. A. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.03.006 · Cited by 157
Bleeker, W. K., van Bueren, J. J. L., van Ojik, H. H., Gerritsen, A. F., Pluyter, M., Houtkamp, M., Halk, E., Goldstein, J., Schuurman, J., van Dijk, M. A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.7.4699 · Cited by 152
Self-citationGenerating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair
Strop, P., Ho, W.-H., Boustany, L. M., Abdiche, Y. N., Lindquist, K. C., Farias, S., Rickert, M., Appah, C. T., Pascua, E., Radcliffe, T., et al. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.04.020 · Cited by 148
Normal human immunoglobulin G4 is bispecific: it has two different antigen‐combining sites
Schuurman, J., van Ree, R., Perdok, G. J., van Doorn, H. R., Tan, K. Y., & Aalberse, R. C. (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00845.x · Cited by 148
Self-citationLabrijn, A. F., Rispens, T., Meesters, J. I., Rose, R., den Bleker, T. H., Loverix, S., van den Bremer, E. T. J., Neijssen, J., Vink, T., Lasters, I., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003336 · Cited by 137
Self-citationIntrachain disulfide bond in the core hinge region of human IgG4
Bloom, J. W., Madanat, M. S., Marriott, D., Wong, T., & Chan, S. K. (1997) · Protein Science · doi:10.1002/pro.5560060217 · Cited by 130
Bernardis, F. D., Liu, H., O’Mahony, R., Valle, R. L., Bartollino, S., Sandini, S., Grant, S., Brewis, N., Tomlinson, I. M., Basset, R. C., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/509891 · Cited by 114
Moore, G. L., Bautista, C., Pong, E., Nguyen, D.-H. T., Jacinto, J. M., Eivazi, A., Muchhal, U. S., Karki, S., Chu, S. Y., & Lazar, G. A. (2011) · mAbs · doi:10.4161/mabs.3.6.18123 · Cited by 110
Warncke, M., Calzascia, T., Coulot, M., Balke, N., Touil, R., Kolbinger, F., & Heusser, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200090 · Cited by 104
Jäger, M., Schoberth, A., Ruf, P., Hess, J., & Lindhofer, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2861 · Cited by 94
Dimasi, N., Gao, C., Fleming, R. L., Woods, R. M., Yao, X.-T., Shirinian, L., Kiener, P. A., & Wu, H. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.08.032 · Cited by 92
Jackman, J. K., Chen, Y., Huang, A. J. Y., Moffat, B., Scheer, J. M., Leong, S. R., Lee, W. P., Zhang, J., Sharma, N., Lu, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113910 · Cited by 91
Rose, R., Labrijn, A. F., van den Bremer, E. T. J., Loverix, S., Lasters, I., van Berkel, P. H. C., van de Winkel, J. G. J., Schuurman, J., Parren, P. W. H. I., & Heck, A. J. R. (2011) · Structure · doi:10.1016/j.str.2011.06.016 · Cited by 85
Self-citationDong, J., Sereno, A., Aivazian, D., Langley, E. J., Miller, B., Snyder, W. B., Chan, E., Cantele, M., Morena, R., Joseph, I. B. J., et al. (2011) · mAbs · doi:10.4161/mabs.3.3.15188 · Cited by 81
Engineering of stable bispecific antibodies targeting IL-17A and IL-23
Mabry, R., Lewis, K. E., Moore, M. D., McKernan, P. A., Bukowski, T. R., Bontadelli, K., Brender, T., Okada, S. L., Lum, K. D., West, J. W., et al. (2009) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp073 · Cited by 64
Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1
Nesspor, T., Raju, T. S., Chin, C., Vafa, O., & Brezski, R. J. (2012) · Journal of Molecular Recognition · doi:10.1002/jmr.2155 · Cited by 53
Davol, P. A., Smith, J. A., KOUTTAB, N. M., Elfenbein, G. J., & Lum, L. G. (2004) · Clinical Prostate Cancer · doi:10.3816/cgc.2004.n.021 · Cited by 38
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Self-citationThe making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 796
Self-citationAntibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Metadata
- Authors
- Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., van Berkel, P. H. C., van de Winkel, J. G. J., Schuurman, J., & Parren, P. W. H. I.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-03-11
- Volume
- 110
- Issue
- 13
- Pages
- 5145-5150
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2168356942
- Cited by
- 339
- References
- 43
- FWCI
- 17.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.